3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
76
Neoplasm Metastasis
12
Neoplasms
10
Neoplasms by Site
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Breast Diseases
3
Recurrence
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumors
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
capivasertib
2
Fulvestrant
2
ribociclib
1
palbociclib
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
palbociclib
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled